PRIMARY STUDY
Inhibition of cerebral type 1 cannabinoid receptors is associated with impaired auditory mismatch negativity generation in the ketamine model of schizophrenia
Key Findings: The endogenous cannabinoid system appears to be involved in auditory sensory memory, especially with CB(1) receptor antagonism which may impair cognitive performance by a disturbed interaction between endocannabinergic activity and glutamatergic neurotransmission as seen in schizophrenia.
Type of Study: Double Blind Clinical Trial
Study Sample Size: 24
Study Result: Positive
Research Location(s): Germany
Year of Pub: 2011
Cannabinoids Studied: SR-x Synthetic Cannabinoids, Endocannabinoid (unspecified)
Phytocannabinoid Source: Not Applicable
Receptors Studied: CB1, CB1 antagonist
Ligands Studied: Glutamate
DOSING DETAILS 
Study Dosing Objective: Effective Dose, Synergistic Dose
Clinical Relevance: The endogenous cannabinoid system appears to be involved in auditory sensory memory, especially with CB(1) receptor antagonism which may impair cognitive performance by a disturbed interaction between endocannabinergic activity and glutamatergic neurotransmission as seen in schizophrenia.
Additional Notes: Pharmacokinetic Study Data, Pharmacodynamic Study Data
Citation: Roser P, et al. Inhibition of cerebral type 1 cannabinoid receptors is associated with impaired auditory mismatch negativity generation in the ketamine model of schizophrenia. Psychopharmacology (Berl). 2011; 218:611-20. doi: 10.1007/s00213-011-2352-y
Authors: Roser P, Haussleiter IS, Chong HJ, Maier C, Kawohl W, Norra C, Juckel G
